Immunocore Reports the First Patient Dosing with IMC-P115C in P-I Study to Treat Tumors Expressing PRAME
Shots:
- Immunocore has dosed the first patient with IMC-P115C (PRAME-HLE-A02) under its P-I clinical evaluation for treating tumors with PRAME expression
- The dose escalation P-I (IMC-P115C-1005) study will assess the safety, PK & preliminary anti-tumor activity of IMC-P115C in HLA-A*02:01+ patients with advanced cancers expressing PRAME
- IMC-P115C is a bispecific protein with extended half-life that targets PRAME peptide & CD3, similar to brenetafusp, and is the sixth ImmTAC candidate to enter clinical trials
Ref: Immunocore | Image: Immunocore
Related News:- Immunocore Entered into an Agreement with Gadeta to Develop Gamma Delta TCR ImmTAC for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
